This provides the unique opportunity to harness the cytotoxic capacity of T-cells to selectively target cancer cells without harming EGFR-positive healthy tissues, thereby EGFRvIII/CD3 TandAb therapeutics might offer superior safety and patient convenience, while achieving highly efficacious tumor control. Here, EGFR is linked to neoplasm.